Explore the positions available across Oxford Science Enterprises

T-Cypher Bio

tcypherbio.com

T-Cypher Bio is an early-stage, innovative biotechnology company based in Oxford, UK. We believe that TCR-based therapeutics have the potential to transform the treatment of solid tumors, as well as autoimmune and inflammatory conditions. Yet challenges in the identification of therapeutically relevant targets and TCRs have limited the application of such therapies. Our goals: - Develop next-generation TCR therapies for the treatment of cancer and autoimmune disease. - Innovate to make TCR therapies widely available to patients. About T-Cypher: - Founded in 2021 based on exclusive technology licenses from the University of Oxford, and with Oxford Science Enterprises as the major shareholder. - Proprietary disease target and TCR discovery platform. - Expanding TCR bank against novel, differentiated targets. - Differentiated approach to multiplexing TCRs in therapeutic T-cells. - Diverse team with experienced leadership from prominent companies covering cell therapy and gene engineering.